Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Harvard Business School
Medtronic
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 9,187,559

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,187,559
Title:Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Abstract: Multiple-variable dose methods for treating TNF.alpha.-related disorders, including Crohn\'s disease and psoriasis, comprising administering TNF.alpha. inhibitors, including TNF.alpha. antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Inventor(s): Hoffman; Rebecca S. (Wilmette, IL), Chartash; Elliot K. (Randolph, NJ), Taylor; Lori K. (Wadsworth, IL), Granneman; George R. (Lindenhurst, IL), Yan; Philip (Vernon Hills, IL)
Assignee: AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:14/628,068
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,187,559
Patent Claims:see list of patent claims

Details for Patent 9,187,559

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2021-03-07 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial AbbVie Biotechnology Ltd (Hamilton, BM) 2021-03-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
McKesson
McKinsey
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.